Meet representatives of Affimed Therapeutics AG on following conferences:
| Target Cancer Therapies, London, UK 26. - 27.05.2010 "Increased anti-tumor activity using targeted antibody therapeutics " speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed |
| Recombinant Antibodies 2010, Berlin Germany, 14. -18.06.2010 "Bispecific TandAbs for recruitment of T and NK cells", speaker: Prof. Dr. Melvyn Little, CSA, deputy CEO of Affimed |
| Next Generation Antibodies for Cancer Drugs, Geneve, Switzerland, 09.06.2009 Speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed |
| Bio Equity, München, Germany, 09. -10.06.2009 Dr. Rolf Günther, CEO of Affimed |
| Bio Capital Europe 2009, Amsterdam Netherlands, 21.04.2009 "Company presentation"; speaker: Dr. Rolf Günther, CEO of Affimed |
| Bio Europe 2008, Mannheim Germany 17. - 19.11.2008 "Company presentation"; speaker: Dr. Volker Lang, CBO of Affimed |
| Proteins Congress 2008, Berlin, Germany 20. - 21.11.2008 "Engineering Second Generation Antibody Formats for Clinical Applications" speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed |
| The 25th International Conference "Advances in the Application of the Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer stem Cells"
Island of Rhodes, Greece, 16 - 18.06.2008 "Alternative antibody formats: fusions and fragments"; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO of Affimed "Development of a bispecific tetravalent antibody for killing of EpCAM positive cells"; speaker: Dr. Fabrice le Gall, Head of Engineering, Affimed |
| Bio International Convention 2008, San Diego, USA 17. - 20.06.2008 Gavin D. Clark, Vice President Business Development, Dr. Volker Lang, CBO of Affimed, Dr. Stephan Knackmuss, Head of Sreening, Affimed, Partnering Forum |
| BioEquity, Amsterdam, Netherlands, 28. - 29.05.2008 Dr Florian Fischer, CFO of Affimed |
| 2. Ernst & Young Life Science Day, Neue Börse Frankfurt/ Main, Germany, 08.05.2008 Dr. Rolf Günther, CEO of Affimed |
| BFF Biotech & Finance Forum, Stuttgart, Germany, 28.04.2008 Presentation of Dr. Florian Fischer, CFO of Affimed |
| AACR (American Association for Cancer Research)Annual Meeting 2008, San Diego, USA 12. -16.04.2008 Poster Session, 15. 04.2008 at 1 p.m >Development of a bispecific tetravalent antibody for treating Hodgkin's Disease<; Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed, Dr. Uwe Reusch, Head of Cell Culture, Affimed |
| Bio Europe Spring, Madrid, Spain, 07. - 09.04.2008 |
| Bio Capital Europe 2008, Amsterdam, Netherlands, 05.03.2008 speaker: Dr Rolf Günther, CEO of Affimed |
| 24th International Conference: "Advances in the Application of Monoclonal Antibodies in Clinical Oncology", Cyprus 16. 06.-20.06.2007 >Recruitment of NK cells for lysing tumor cells<; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed |
| University of Vienna, Austria, 01.06.2007 >The recruitment of immune effector cells to lyse tumor cells using recombinant antibodies<; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed |
|
BIO 2007 International Convention, Boston, MA, USA, 06.-09.05.2007 www.bio2007.org |
|
BioCapital Europe 2007, Amsterdam, Netherlands, 28.03.2007 speaker: Dr Rolf Günther, CEO of Affimed www.biocapitaleurope.com |
|
Antibodies in Discovery and Development, London, 28.-29.03.2007 »Increasing efficiency and productivity of technology, research and development of therapeutic antibody candidates«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed |
|
World Biopharm Forum 2007, Development of new therapies for cancer, New Hall, Cambridge, UK, 19.-21.03.2007 »Exploiting the potential of NK cells to kill tumor cells«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed |
|
New Binding Proteins Conference, Halle, 01.-03.03.2007 »Recruitment of immune cells to destroy tumor cells using novel antibody products«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed |
|
Symposium Universitäts-Kinder- und Jugendklinik, Rostock, 23.-24.02.2007 »Rekombinante multivalente Antikörper für den Einsatz in der Onkologie«; speaker: Prof. Dr. Melvyn Little, CSO, deputy CEO, Affimed |